Milo Biotechnology Announces FDA Orphan Drug Designation for Treatment of Inclusion Body Myositis

Milo Biotechnology announces its gene therapy has been granted Orphan Drug designation from the FDA’s Office of Orphan Products Development for treatment of inclusion body myositis.